FY23 PCARP Focus Areas
• Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities • Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during diagnosis, treatment, and survivorship • Barriers to the implementation of health care, including ways to overcome socioeconomic, geographic, or ethnic and racial disparities • Identification and characterization of pancreatic cancer risk including genetic and environmental risk factors, such as diet, obesity, and microbiome • Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia • Understanding tumor development and progression, from precursors to metastasis • Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response • Biomarkers to predict therapeutic response and guide management strategies • New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance
The anticipated direct costs budgeted for the entire period of performance for an FY23 PCARP Translational Research Partnership Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.